Suganya Selvarajah

Suganya Selvarajah has worked in the field of biology for over 17 years. Suganya began their career in 2002 as a Post Doctoral Fellow at The Scripps Research Institute, where they worked on an International Aids Vaccine Initiative (IAVI) funded project on HIV-1 Vaccine design. Suganya then moved to UCSF and BSRI in 2008, where they were a Staff Scientist and was awarded a NIH R21 grant as Principal Investigator (May 2012- April 2015) to study Biomarkers of Spontaneous HCV infection in plasma of HCV infected human cohorts with known outcome of infection. In 2011, they were a Consultant at Novartis. From 2012 to 2019, they were Director-Head of Virology and Neurobiology at Prosetta Corporation, where they developed small-molecule inhibitors of host protein targets for respiratory viruses such as FLUV, RSV, Coronavirus as well as CNS program focused on ALS and PD therapeutics. In 2019, they became the Head of Immunology, Research and Development at ARAVASC, INC. and Director of Biology at Attralus.

Suganya Selvarajah holds a Doctor of Philosophy (Ph.D.) in Virology and Immunology from The University of Edinburgh.